autologous blood and marrow transplantation - Blog Science ...

1.0-1 +
0.2
Miller et al. 5
Event Free Survival
o.o ^ ^ ^ i , , ,
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140
MONTHS
Figure 1. Disease-free survival of 70 patients with AML in CR2 or CR3 who received aut
grafts purged with 4HC at Johns Hopkins.
vs. no purging that included 295 patients in first or second remission who were
transplanted between 1989 and 1993. Initial analysis of the data was performed in
1995 when the median follow-up was 25 months. Several baseline characteristics
were significantly different between the two groups. Patients in first remission who
received 4HC-purged grafts were more likely to be younger, were less likely to
have received consolidation chemotherapy, and were transplanted earlier in
remission. Patients in second remission receiving 4HC-purged autograft were more
likely to have relapsed within 1 year of first remission compared with those
receiving an unpurged autograft (62 vs. 19%). To account for these differences, a
forward stepwise model was built to test the effect of purging on time to treatment
failure. Using this model, the risk of treatment failure was significantly lower using
4HC-purged grafts compared with unpurged grafts. Other significant covariates for
treatment failure were first remission duration, number of cycles of consolidation